| MeSH term | MeSH ID | Detail |
|---|---|---|
| Uremia | D014511 | 33 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Neoplasms, Experimental | D009374 | 10 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ha H et al. | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. | 2003 | J. Biol. Chem. | pmid:12637570 |
| Ritchlin CT et al. | Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. | 2003 | J. Clin. Invest. | pmid:12639988 |
| Takahashi E et al. | High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. | 2002 | J. Med. Dent. Sci. | pmid:12641381 |
| Fox SW et al. | The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. | 2003 | J. Immunol. | pmid:12646633 |
| Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
| Wise GE et al. | Regulation of osteoprotegerin gene expression in dental follicle cells. | 2003 | J. Dent. Res. | pmid:12651935 |
| Schoppet M et al. | Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. | 2003 | Circulation | pmid:12654623 |
| Nakano M et al. | Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. | 2003 | Oral Dis | pmid:12657033 |
| Ra JS et al. | Osteoprotegerin inhibits proliferation of myeloid progenitor cells. | 2003 | J. Hematother. Stem Cell Res. | pmid:12662434 |
| Szalay F et al. | High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. | 2003 | J. Hepatol. | pmid:12663228 |
| Okada Y et al. | Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. | 2003 | J. Biol. Chem. | pmid:12665515 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Terpos E et al. | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. | 2003 | Blood | pmid:12689925 |
| Zheng B et al. | MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. | 2003 | Blood | pmid:12689928 |
| Moreno JL et al. | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. | 2003 | Blood | pmid:12689929 |
| Dovio A et al. | Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. | 2003 | J. Endocrinol. | pmid:12697042 |
| Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
| Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
| Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Al-Qawasmi RA et al. | Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. | 2003 | J. Dent. Res. | pmid:12709501 |
| Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
| Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
| Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
| Yonou H et al. | Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2003 | Cancer Res. | pmid:12727825 |
| Capparelli C et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | 2003 | J. Bone Miner. Res. | pmid:12733724 |
| Wong T et al. | Therapeutic implications for interferon-alpha in arthritis: a pilot study. | 2003 | J. Rheumatol. | pmid:12734885 |
| Lee ZH and Kim HH | Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12745060 |
| Boyle WJ et al. | Osteoclast differentiation and activation. | 2003 | Nature | pmid:12748652 |
| Kanatani M et al. | Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. | 2003 | J. Cell. Physiol. | pmid:12767054 |
| Cheung J et al. | Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. | 2003 | J. Endocrinol. | pmid:12773123 |
| Nimmanapalli R and Bhalla K | Targets in apoptosis signaling: promise of selective anticancer therapy. | 2003 | Methods Mol. Biol. | pmid:12777745 |
| Garber K | Why it hurts: researchers seek mechanisms of cancer pain. | 2003 | J. Natl. Cancer Inst. | pmid:12783923 |
| Liu B et al. | Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. | 2003 | J. Oral Pathol. Med. | pmid:12787044 |
| Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
| Eaton CL and Coleman RE | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. | 2003 | Cancer Treat. Rev. | pmid:12787713 |
| Fahrleitner-Pammer A et al. | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. | 2003 | Wien. Klin. Wochenschr. | pmid:12793029 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
| Kido S et al. | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. | 2003 | Bone | pmid:12810169 |
| Kudlacek S et al. | Serum levels of osteoprotegerin increase with age in a healthy adult population. | 2003 | Bone | pmid:12810175 |
| Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
| Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
| Ikeda T et al. | Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. | 2003 | Pathol. Int. | pmid:12828610 |
| Crotti T et al. | Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. | 2003 | J. Periodont. Res. | pmid:12828654 |
| Tazoe M et al. | Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. | 2003 | Arch. Oral Biol. | pmid:12828991 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Terpos E et al. | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. | 2003 | Int. J. Cancer | pmid:12845688 |
| Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
| Fizazi K et al. | Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. | 2003 | Clin. Cancer Res. | pmid:12855635 |
| Okuma K et al. | Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. | 2003 | J. Virol. | pmid:12857926 |
| Cheng X et al. | The TNF receptor superfamily: role in immune inflammation and bone formation. | 2003 | Immunol. Res. | pmid:12857975 |
| Shin MM et al. | High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. | 2003 | Exp. Mol. Med. | pmid:12858015 |
| Glossop JR et al. | No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. | 2003 | J. Rheumatol. | pmid:12858434 |
| Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |
| Bridgham JT and Johnson AL | Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12878204 |
| Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
| Sasaki T | Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. | 2003 | Microsc. Res. Tech. | pmid:12879416 |
| Helfrich MH | Osteoclast diseases. | 2003 | Microsc. Res. Tech. | pmid:12879419 |
| Younes A and Aggarwall BB | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. | 2003 | Cancer | pmid:12879461 |
| Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
| Min JK et al. | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. | 2003 | J. Biol. Chem. | pmid:12893832 |
| Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
| Si AI et al. | Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. | 2003 | J. Cell. Biochem. | pmid:12898514 |
| Nitta K et al. | The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. | 2003 | Am. J. Kidney Dis. | pmid:12900812 |
| Hampson G et al. | Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. | 2003 | Osteoporos Int | pmid:12904840 |
| Misra M et al. | Serum osteoprotegerin in adolescent girls with anorexia nervosa. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915674 |
| Lonergan M et al. | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915677 |
| Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
| Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
| Nawroth P et al. | [Osteoporosis and cardiovascular disease--two sides of the same coin?]. | 2003 | Med. Klin. (Munich) | pmid:12928809 |
| Nakatsuka K et al. | Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. | 2003 | J. Bone Miner. Res. | pmid:12929927 |
| Li JP and Ling JQ | [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2003 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:12930661 |
| Schett G et al. | The role of osteoprotegerin in arthritis. | 2003 | Arthritis Res. Ther. | pmid:12932284 |
| Karsdal MA et al. | Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. | 2003 | J. Biol. Chem. | pmid:12933809 |
| Benevolenskaia LI | [Issues of osteoporosis in present-day medicine]. | 2003 | Vestn. Akad. Med. Nauk SSSR | pmid:12934464 |
| Sugatani T et al. | Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. | 2003 | J. Cell. Biochem. | pmid:12938156 |
| Yamagami H et al. | Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. | 2003 | Biochem. Pharmacol. | pmid:12948861 |
| Srivastava S et al. | Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. | 2003 | J. Biol. Chem. | pmid:12952963 |
| Lee HA et al. | Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. | 2003 | Exp. Physiol. | pmid:12955156 |
| Yorke R et al. | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. | 2003 | Eur. J. Cancer | pmid:12957466 |
| Zhang L et al. | The role of calmodulin in the regulation of osteoclastogenesis. | 2003 | Endocrinology | pmid:12960067 |
| Nakamura H et al. | Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. | 2003 | J. Med. Dent. Sci. | pmid:12968638 |
| Viereck V et al. | Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12970288 |
| Kaneyama K et al. | Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. | 2003 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:12973279 |
| Sakurai A et al. | Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. | 2003 | Infect. Immun. | pmid:14500523 |
| Kim HH et al. | RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. | 2003 | FASEB J. | pmid:14500543 |
| Nakamura M et al. | Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. | 2003 | Endocrinology | pmid:14500574 |
| Zhang Z et al. | Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. | 2003 | J. Immunol. | pmid:14500659 |
| Naumann U et al. | Expression and functional activity of osteoprotegerin in human malignant gliomas. | 2004 | Acta Neuropathol. | pmid:14504888 |
| Ueno Y et al. | In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. | 2003 | J. Cell. Biochem. | pmid:14505343 |
| Kaneyama K et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. | 2003 | Int J Oral Maxillofac Surg | pmid:14505625 |